IS5943A - Aðferð og samsetningar til að endurheimta samræmdan stöðugleika próteina af p53 ættinni - Google Patents
Aðferð og samsetningar til að endurheimta samræmdan stöðugleika próteina af p53 ættinniInfo
- Publication number
- IS5943A IS5943A IS5943A IS5943A IS5943A IS 5943 A IS5943 A IS 5943A IS 5943 A IS5943 A IS 5943A IS 5943 A IS5943 A IS 5943A IS 5943 A IS5943 A IS 5943A
- Authority
- IS
- Iceland
- Prior art keywords
- genus
- proteins
- combinations
- uniform stability
- restoring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11054298P | 1998-12-02 | 1998-12-02 | |
PCT/IB1999/001916 WO2000032175A2 (en) | 1998-12-02 | 1999-12-01 | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
Publications (1)
Publication Number | Publication Date |
---|---|
IS5943A true IS5943A (is) | 2001-05-15 |
Family
ID=22333594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS5943A IS5943A (is) | 1998-12-02 | 2001-05-15 | Aðferð og samsetningar til að endurheimta samræmdan stöðugleika próteina af p53 ættinni |
Country Status (25)
Country | Link |
---|---|
US (1) | US20020048271A1 (is) |
EP (1) | EP1137418A2 (is) |
JP (2) | JP2002531396A (is) |
KR (1) | KR20010086073A (is) |
CN (1) | CN1329493A (is) |
AP (1) | AP2001002153A0 (is) |
AU (1) | AU1290700A (is) |
BG (1) | BG105599A (is) |
BR (1) | BR9915940A (is) |
CA (1) | CA2350597A1 (is) |
EA (1) | EA003326B1 (is) |
EE (1) | EE200100302A (is) |
HK (1) | HK1041644A1 (is) |
HR (1) | HRP20010414A2 (is) |
HU (1) | HUP0201215A2 (is) |
ID (1) | ID29061A (is) |
IL (1) | IL143094A0 (is) |
IS (1) | IS5943A (is) |
NO (1) | NO20012737L (is) |
OA (1) | OA11722A (is) |
PL (1) | PL348310A1 (is) |
TR (1) | TR200101549T2 (is) |
WO (1) | WO2000032175A2 (is) |
YU (1) | YU35401A (is) |
ZA (1) | ZA200104210B (is) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
WO2003000853A2 (en) * | 2001-06-20 | 2003-01-03 | Caprion Pharmaceuticals Inc. | Protein aggregation assays and uses thereof |
EP1414846A2 (en) * | 2001-08-10 | 2004-05-06 | Medical Research Council | Molecule |
WO2004034013A2 (en) * | 2002-05-06 | 2004-04-22 | Colorado State University Research Foundation | Genotoxicity analysis |
WO2004030671A2 (en) * | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
DE60307049T2 (de) * | 2003-04-25 | 2007-02-08 | Neuro3D | Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS |
US6970791B1 (en) * | 2003-05-23 | 2005-11-29 | Verachem, Llc | Tailored user interfaces for molecular modeling |
CN1984660B (zh) * | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉 |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
US20070099950A1 (en) * | 2003-11-21 | 2007-05-03 | Jongwon Lim | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
WO2005061001A1 (ja) * | 2003-12-24 | 2005-07-07 | Locomogene, Inc. | 癌の抑制方法 |
JPWO2005061007A1 (ja) * | 2003-12-24 | 2007-07-12 | 学校法人 聖マリアンナ医科大学 | 癌の抑制方法 |
AU2005251735A1 (en) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
US20070015774A1 (en) * | 2005-07-15 | 2007-01-18 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
US7790474B1 (en) | 2005-07-15 | 2010-09-07 | Schering Corporation | p53 modulators |
WO2007107545A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
WO2007107543A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
NZ546477A (en) * | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
WO2008008358A2 (en) * | 2006-07-10 | 2008-01-17 | Columbia University | Anti-cocaine compositions and treatment |
WO2008155441A1 (en) * | 2007-06-20 | 2008-12-24 | Marikki Laiho | Activators and therapeutic applications thereof |
US8637009B2 (en) | 2007-07-10 | 2014-01-28 | The Trustees Of Columbia University In The City Of New York | Thermostabilization of proteins |
ES2534899T3 (es) | 2007-08-06 | 2015-04-30 | Janssen Pharmaceutica, N.V. | Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53 |
MY152018A (en) | 2009-02-04 | 2014-08-15 | Janssen Pharmaceutica Nv | Indole derivatives as anticancer agents |
WO2011127406A2 (en) * | 2010-04-09 | 2011-10-13 | The Brigham And Women's Hospital, Inc. | Acridines as inhibitors of haspin and dyrk kinases |
US9221760B2 (en) | 2011-05-09 | 2015-12-29 | Van Andel Research Institute | Autophagy inhibitors |
US9187439B2 (en) | 2011-09-21 | 2015-11-17 | Inception Orion, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
CN102660257B (zh) * | 2012-05-22 | 2013-11-27 | 南京邮电大学 | 吩噻嗪基喹唑啉类荧光离子探针及其应用 |
EP3201234B1 (en) * | 2014-09-30 | 2018-11-07 | Diadem S.r.l. | Antibody binding a linear epitope of human p53 and diagnostic applications thereof |
CN105399671B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
CN105399670B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途 |
CN105418501B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
US11230578B2 (en) | 2016-02-04 | 2022-01-25 | Yeda Research And Development Co. Ltd. | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53 |
CN109069481A (zh) | 2016-02-19 | 2018-12-21 | 皮姆维制药公司 | 用于恢复突变p53功能的方法和化合物 |
CN109694358B (zh) * | 2019-01-23 | 2022-02-08 | 广西师范大学 | 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用 |
AU2020352516A1 (en) | 2019-09-23 | 2022-04-14 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
IL298592A (en) | 2020-06-24 | 2023-01-01 | Pmv Pharmaceuticals Inc | Combined treatment for cancer |
GB202111035D0 (en) * | 2021-07-30 | 2021-09-15 | Vestlandets Innovasjonsselskap As | Therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
EP0746613B1 (en) * | 1994-03-08 | 2006-05-24 | Memorial Sloan-Kettering Cancer Center | Recombinant humanized anti-fb5 antibodies |
WO1996018725A1 (en) * | 1994-12-13 | 1996-06-20 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
US6107332A (en) * | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
WO1997037645A1 (en) * | 1996-04-10 | 1997-10-16 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
US6270954B1 (en) * | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
DE19624154A1 (de) * | 1996-06-18 | 1998-01-08 | Hoechst Ag | Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung |
US5932613A (en) * | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
EP0923561B1 (en) * | 1996-08-28 | 2002-10-23 | The Procter & Gamble Company | Heterocyclic metalloprotease inhibitors |
UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6387673B1 (en) * | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US6284923B1 (en) * | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
US6387903B1 (en) * | 1997-08-27 | 2002-05-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
FI105554B (fi) * | 1998-05-13 | 2000-09-15 | Galilaeus Oy | Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit |
US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
DE69921151T2 (de) * | 1998-08-12 | 2005-06-02 | Daiichi Pure Chemicals Co. Ltd. | Fluorszierende marker |
SE9900941D0 (sv) * | 1998-12-23 | 1999-03-16 | Nomet Management Serv Bv | Novel retinoic acid derivatives and their use |
US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
WO2000066125A1 (en) * | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6406699B1 (en) * | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
AU7847800A (en) * | 1999-10-15 | 2001-04-30 | Mayo Foundation For Medical Education And Research | Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia |
US6372785B1 (en) * | 2000-05-04 | 2002-04-16 | Keith Chan, President Globoasia, Llc | Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon |
US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
US6395771B1 (en) * | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6391916B1 (en) * | 2000-07-21 | 2002-05-21 | The Hong Kong University Of Science And Technology | Enediyne derivatives |
-
1999
- 1999-12-01 JP JP2000584871A patent/JP2002531396A/ja active Pending
- 1999-12-01 IL IL14309499A patent/IL143094A0/xx unknown
- 1999-12-01 AU AU12907/00A patent/AU1290700A/en not_active Abandoned
- 1999-12-01 ID IDW00200101178A patent/ID29061A/id unknown
- 1999-12-01 EA EA200100502A patent/EA003326B1/ru not_active IP Right Cessation
- 1999-12-01 PL PL99348310A patent/PL348310A1/xx unknown
- 1999-12-01 OA OA1200100136A patent/OA11722A/en unknown
- 1999-12-01 YU YU35401A patent/YU35401A/sh unknown
- 1999-12-01 HU HU0201215A patent/HUP0201215A2/hu unknown
- 1999-12-01 TR TR2001/01549T patent/TR200101549T2/xx unknown
- 1999-12-01 KR KR1020017006830A patent/KR20010086073A/ko not_active Application Discontinuation
- 1999-12-01 CA CA002350597A patent/CA2350597A1/en not_active Abandoned
- 1999-12-01 EP EP99956270A patent/EP1137418A2/en not_active Withdrawn
- 1999-12-01 EE EEP200100302A patent/EE200100302A/xx unknown
- 1999-12-01 WO PCT/IB1999/001916 patent/WO2000032175A2/en not_active Application Discontinuation
- 1999-12-01 CN CN99814010A patent/CN1329493A/zh active Pending
- 1999-12-01 BR BR9915940-6A patent/BR9915940A/pt not_active IP Right Cessation
- 1999-12-01 AP APAP/P/2001/002153A patent/AP2001002153A0/en unknown
-
2001
- 2001-05-15 IS IS5943A patent/IS5943A/is unknown
- 2001-05-23 US US09/863,976 patent/US20020048271A1/en not_active Abandoned
- 2001-05-23 ZA ZA200104210A patent/ZA200104210B/en unknown
- 2001-05-29 HR HR20010414A patent/HRP20010414A2/hr not_active Application Discontinuation
- 2001-06-01 NO NO20012737A patent/NO20012737L/no not_active Application Discontinuation
- 2001-06-14 BG BG105599A patent/BG105599A/xx unknown
-
2002
- 2002-05-04 HK HK02103378.4A patent/HK1041644A1/zh unknown
-
2006
- 2006-01-06 JP JP2006001475A patent/JP2006166920A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2350597A1 (en) | 2000-06-08 |
YU35401A (sh) | 2005-07-19 |
WO2000032175A2 (en) | 2000-06-08 |
EE200100302A (et) | 2002-08-15 |
ID29061A (id) | 2001-07-26 |
BG105599A (en) | 2002-02-28 |
HRP20010414A2 (en) | 2002-06-30 |
PL348310A1 (en) | 2002-05-20 |
EA003326B1 (ru) | 2003-04-24 |
NO20012737D0 (no) | 2001-06-01 |
NO20012737L (no) | 2001-07-09 |
US20020048271A1 (en) | 2002-04-25 |
AU1290700A (en) | 2000-06-19 |
JP2002531396A (ja) | 2002-09-24 |
KR20010086073A (ko) | 2001-09-07 |
ZA200104210B (en) | 2003-02-24 |
IL143094A0 (en) | 2002-04-21 |
EA200100502A1 (ru) | 2001-12-24 |
AP2001002153A0 (en) | 2001-06-30 |
WO2000032175A3 (en) | 2000-08-03 |
CN1329493A (zh) | 2002-01-02 |
BR9915940A (pt) | 2001-09-11 |
HUP0201215A2 (en) | 2002-08-28 |
HK1041644A1 (zh) | 2002-07-19 |
JP2006166920A (ja) | 2006-06-29 |
EP1137418A2 (en) | 2001-10-04 |
OA11722A (en) | 2005-01-25 |
TR200101549T2 (tr) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS5943A (is) | Aðferð og samsetningar til að endurheimta samræmdan stöðugleika próteina af p53 ættinni | |
DK0975708T3 (da) | Fremgangsmåder og materialer til nedbrydning af xanthan | |
DK0950138T3 (da) | Fremgangsmåder og materialer til fremstilling af papir | |
NO985278D0 (no) | Elektromagnetiske-til-akustiske og akustiske-til-elektro-magnetiske forsterkere og fremgangsmÕter for bruk av disse | |
DK0996728T3 (da) | Forbedrede anti-IgE antistoffer og fremgangsmåde til forbedring af antistoffer | |
NO20002846D0 (no) | Inhaleringsanordning og fremgangsmÕte ved samme | |
DK0877752T3 (da) | Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler | |
DK0850948T3 (da) | Propiophenonderivater og fremgangsmåde til fremstilling deraf | |
DK1082155T3 (da) | Dispersions-apparater til törpulver og fremgangsmåder til anvendelse af sådanne | |
DK0929230T3 (da) | Fremgangsmåde til dannelse af blødgjorte proteinholdige materialer og sammensætninger deraf | |
NO984031L (no) | Bµreelement og fremgangsmÕte for fremstilling av samme | |
DK0865577T3 (da) | Turbomaskineri og fremgangsmåde til fremstilling af samme | |
DK1140824T3 (da) | Fremgangsmåde til fremstilling af 3-alkanoyl- og 3-alkylindoler | |
DK0917879T3 (da) | Forbedret fremgangsmåde til stabilisering af proteiner | |
DK70896A (da) | Fremgangsmåde og anlæg til fremstilling af spiseispinde | |
DK0902620T3 (da) | Midler og fremgangsmåder til bekæmpelse af skadelige svampe | |
DK0751132T3 (da) | Pyridazinonderivater og fremgangsmåder til fremstilling af samme | |
NO20006059L (no) | Sammensatt element og fremgangsmåte for anvendelse | |
NO940801L (no) | Fremgangsmåte og komponenter for alternativ forskaling | |
DK0864564T3 (da) | Særlig fremgangsmåde til fremstillingen af alfa-bromlactamderivater | |
DK0905128T3 (da) | Fremgangsmåder og mellemprodukter egnede til fremstilling af antifolater | |
DK0983249T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater | |
FI971707A0 (fi) | Ohjelmoitava vahvistin | |
DK1020524T3 (da) | Mutant bioluminescerende protein og fremgangsmåde til fremstilling af det mutante bioluminescerende protein | |
NO20004553D0 (no) | Blandinger og fremgangsmÕter for oljefeltanvendelser |